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Editorial
Usher syndrome (USH) is an inherited syndromic disorder that 
is characterized by retinitis pigmentosa (RP) and sensorineural 
hearing loss with or without vestibular dysfunction. There are 
three types of USH, with distinct phenotypes [1,2]. Type I (USH1) 
is the most severe form of USH, characterized by severe congeni-
tal deafness, vestibular dysfunction, and prepubertal RP onset. 
In type II (USH2), hearing loss is less severe, vestibular symptoms 
are not present, and the onset of RP occurs around puberty. Type 
III (USH3) shows postlingual progressive hearing loss with or 
without vestibular symptoms, and the onset of RP is quite vari-
able, as it occurs in people in their 20s to 40s. Currently, 400,000 
people worldwide are estimated to be affected by USH. Howev-
er, only 1% of these cases have been officially identified (https://
www.ushersyndromesociety.org/who-we-are/usher-syndrome-
facts.html). USH is responsible for 3% to 6% of cases of early 
childhood deafness. Therefore, early diagnosis, counseling, inter-
vention, and auditory rehabilitation are important to treat USH.
To date, USH has been traced to 16 causative genes and three 
unidentified loci (https://sph.uth.edu/retnet/sum-dis.htm#A-
genes), implying wide genetic heterogeneity of this syndrome. 
In addition, mutations in these genes have shown a broad de-
gree of clinical variability, ranging from nonsyndromic hearing 
loss to isolated RP. Given the clinical and genetic heterogeneity 
of this condition, patients with a milder phenotype tend to be 
underdiagnosed [3]. Therefore, confirming a genetic diagnosis 
for patients with USH remains a challenge, even if we identify 
underlying variants in the potentially causative genes of USH. 
To make an accurate genetic diagnosis of USH with an indefi-
nite phenotype, it is crucial to be familiar with the precise corre-
lations between genotypes and phenotypes. Recently, Lee et al. 
[4] reported two probands with USH2, who manifested postlin-
gual deafness and late-onset RP. In their study, compound het-
erozygous mutations in USH2A were identified in each family, 
and two novel variants (c.1823G>A:p.C608Y and c.14835delT: 
p.G4371fs) were found. Notably, that the proband carrying two 
nonsense variants (p.S4945fs and p.G4371fs) showed more se-
vere hearing loss than the other proband, who carried a non-
sense (p.R2723X) and a missense (p.C608Y) variant. This is also 
consistent with previous studies reporting that patients with trun-
cating variants of USH2A showed more severe and earlier-onset 
hearing loss than those with missense variants [5,6]. Based on 
this evidence, we know that nonsense variants tend to be more 
functionally deleterious and lead to more severe phenotypes in 
terms of hearing loss. However, further studies are needed to 
confirm age-matched genotype-phenotype correlations and dis-
crepancies in RP phenotypes.
In recent years, USH has emerged as a target for gene and mo-
lecular therapy. Several studies have shown that the Ush1c gene 
(encoding harmonin) in Anc80L65 adeno-associated virus (AAV) 
or Whrn (encoding whirlin) in AAV8 was successfully delivered 
into the inner ear of USH mice to restore their auditory and ves-
tibular function [7,8]. It was also reported that antisense oligo-
nucleotide injection to correct a splicing error in the Ush1c gene 
improved hearing function in USH type IC mice [9]. To prepare 
for the upcoming era of precision medicine for hearing loss, we 
need to make genetic diagnoses more reliable and evidence-based. 
To achieve this, the genotype-audiotype correlation should be 
further investigated, and a consortium-based evaluation should 
be performed in the near future.  
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